Moreover, in the first year after transplantation, 129 patients received calcineurin inhibitors and 16 patients received mTOR inhibitors, and there was no statistically significant difference between the two drugs in terms of UTI (p = 0.43). The gene discussed is MTOR; the disease is bacterial urinary tract infection.